ReviewExpert review of gastroenterology & hepatology2019
Review in Expert review of gastroenterology & hepatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety ofFrontiers in oncology · 2022Pooled it
- Dosimetry and pharmacokinetics of [European journal of nuclear medicine and molecular imaging · 2024Trial
- A phase I/II study of the safety and efficacy of [European journal of nuclear medicine and molecular imaging · 2023Trial
- Profiling proteomic responses in small intestinal neuroendocrine tumor GOT1 after [BMC cancer · 2026Article
- Heavy Metal Chelation and Bioprotective Activity of Dextran-DOTA Macromolecular Conjugate.Biomacromolecules · 2026Article
- Peptide-Drug Conjugates for Targeted Delivery in Hematological Malignancies: From Design Principles to Clinical Application.Pharmaceutics · 2026Review
- A 3D co-culture model with fibroblast-restricted FAP expression for cancer therapy using [EJNMMI radiopharmacy and chemistry · 2026Article
- A Phase 0 Imaging Trial of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Review
- Should We Continue Liver Transplantation in Spain for Hepatic Metastases from Neuroendocrine Tumors?Journal of clinical medicine · 2026Article
- Tumor Targeting with Peptide-Drug Conjugates: Showcasing Key Progress and Hurdles.Drug design, development and therapy · 2026Review
- SSTR2-targeting therapy in EBV-positive and EBV-negative metastatic nasopharyngeal carcinoma.American journal of cancer research · 2026Article
- Neo-adjuvant systemic radiation therapy for inoperable hepatic hilum neuroendocrine tumor withAsia Oceania journal of nuclear medicine & biology · 2026Article
- Rare but not forgotten: Therapeutic advancements for rare childhood cancers.Molecular therapy. Oncology · 2025Review
- The Role of Radioligand Therapy in Gastroenteropancreatic Neuroendocrine Tumors: An Italian Expert Opinion.Advances in therapy · 2025Review
- Review
- Review
- A dual-targeting peptide-drug conjugate based on CXCR4 and FOLR1 inhibits triple-negative breast cancer.Acta pharmaceutica Sinica. B · 2025Article
- G Protein-Coupled Receptor Signaling: Implications and Therapeutic Development Advances in Cancers.MedComm · 2025Review
- Safety profile of lanreotide: a retrospective post-marketing pharmacovigilance study based on the real-world data from FAERS database.Endocrine · 2025Article
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.